Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
Classifica tra le azioni #33635
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
Prezzo delle azioni
$0.03702159
Ultima sincronizzazione: 2024-01-29
Capitalizzazione di mercato
$7.21M
Variazione (1 giorno)
-3.08%
Variazione (1 anno)
0.00%
Paese
AU
Scambia Antisense Therapeutics Limited (ANP)

Categoria

Storico del rendimento da dividendi per Antisense Therapeutics Limited (ANP)
Il rendimento da dividendi (TTM) di Antisense Therapeutics Limited (simbolo azionario: ANP) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per Antisense Therapeutics Limited (ANP) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
Non abbastanza dati per le date fornite.
Rendimenti da dividendi (TTM) di aziende simili o concorrenti